Fulgent Genetics (FLGT) Liabilities and Shareholders Equity (2015 - 2026)

Fulgent Genetics has disclosed Liabilities and Shareholders Equity across 12 years of filings, most recently posting $1.1 billion for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 9.22% year-over-year to $1.1 billion; the TTM figure through Jun 2026 stood at $4.7 billion (down 3.82% YoY), while the FY2025 annual figure was $1.2 billion, down 0.53% from the prior year.
• Liabilities and Shareholders Equity came in at $1.1 billion for Q2 2026 at Fulgent Genetics, down from $1.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q1 2022 to a low of $1.1 billion in Q2 2026.
• Average Liabilities and Shareholders Equity over 5 years is $1.3 billion, with a median of $1.2 billion recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity jumped 46.69% in 2022 and slipped 10.87% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.4 billion in 2022, then fell by 10.87% to $1.2 billion in 2023, then slipped by 1.24% to $1.2 billion in 2024, then retreated by 0.53% to $1.2 billion in 2025, then dropped by 10.24% to $1.1 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.1 billion in Q2 2026, $1.2 billion in Q1 2026, and $1.2 billion in Q4 2025.